MX2010001754A - Derivados de azepina como inhibidores de gamma secretasa. - Google Patents

Derivados de azepina como inhibidores de gamma secretasa.

Info

Publication number
MX2010001754A
MX2010001754A MX2010001754A MX2010001754A MX2010001754A MX 2010001754 A MX2010001754 A MX 2010001754A MX 2010001754 A MX2010001754 A MX 2010001754A MX 2010001754 A MX2010001754 A MX 2010001754A MX 2010001754 A MX2010001754 A MX 2010001754A
Authority
MX
Mexico
Prior art keywords
gamma
secretase inhibitors
azepine derivatives
azepine
derivatives
Prior art date
Application number
MX2010001754A
Other languages
English (en)
Spanish (es)
Inventor
Melina Joy Hope Miller
Warren Jaye Porter
Jon Kevin Reel
Almudena Rubio-Esteban
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2010001754A publication Critical patent/MX2010001754A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2010001754A 2007-08-14 2008-08-04 Derivados de azepina como inhibidores de gamma secretasa. MX2010001754A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95572007P 2007-08-14 2007-08-14
PCT/US2008/072049 WO2009023453A1 (en) 2007-08-14 2008-08-04 Azepine derivatives as gamma-secretase inhibitors

Publications (1)

Publication Number Publication Date
MX2010001754A true MX2010001754A (es) 2010-05-14

Family

ID=39811736

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001754A MX2010001754A (es) 2007-08-14 2008-08-04 Derivados de azepina como inhibidores de gamma secretasa.

Country Status (11)

Country Link
US (1) US8188069B2 (enExample)
EP (1) EP2178844A1 (enExample)
JP (1) JP5385904B2 (enExample)
KR (1) KR101136260B1 (enExample)
CN (1) CN101778826B (enExample)
AU (1) AU2008287124B2 (enExample)
BR (1) BRPI0815135A2 (enExample)
CA (1) CA2694209C (enExample)
EA (1) EA017286B1 (enExample)
MX (1) MX2010001754A (enExample)
WO (1) WO2009023453A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076556A2 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
WO2010060088A2 (en) 2008-11-24 2010-05-27 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
WO2013036679A1 (en) * 2011-09-07 2013-03-14 Satori Pharmaceuticals, Inc. Compounds useful for treating neurodegenerative disorders
CA2884309A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity
EP2892506B1 (en) 2012-09-07 2021-11-03 Massachusetts Eye & Ear Infirmary Treating hearing loss with the gamma-secretase inhibitor ly411575
WO2014047393A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds as notch inhibitors
US9133126B2 (en) 2012-09-21 2015-09-15 Bristol-Myers Squibb Company Fluoroalkyl dibenzoazepinone compounds
CN104797584A (zh) 2012-09-21 2015-07-22 百时美施贵宝公司 作为notch抑制剂的三环杂环化合物
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
CN104822665A (zh) 2012-09-21 2015-08-05 百时美施贵宝公司 用作Notch抑制剂的氟烷基和氟环烷基1,4-苯并二氮杂*酮化合物
US9187434B2 (en) 2012-09-21 2015-11-17 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinones compounds
EP2897954B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
JP2015531792A (ja) 2012-09-21 2015-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ １，４−ベンゾジアゼピノン化合物のプロドラッグ
WO2014047374A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds
CN105101968A (zh) 2013-04-04 2015-11-25 百时美施贵宝公司 治疗增殖性疾病的组合疗法
WO2015073524A1 (en) * 2013-11-12 2015-05-21 Drexel University Novel methods of treating or preventing alzheimer's disease
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
EP3212773B1 (en) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
WO2017096233A1 (en) 2015-12-04 2017-06-08 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
CN109219439B (zh) 2016-01-29 2022-09-20 马萨诸塞眼科耳科诊所 内耳支持细胞的扩增和分化及其使用方法
US11564929B2 (en) 2016-04-12 2023-01-31 Eli Lilly And Company Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer
MX380779B (es) 2016-04-12 2025-03-12 Lilly Co Eli Terapia combinatoria con inhibidores notch y cdk4/6
KR102362222B1 (ko) 2016-05-16 2022-02-11 더 제너럴 하스피탈 코포레이션 폐 상피 공학에서 인간 기도 줄기 세포
EP3458091B1 (en) 2016-05-20 2021-11-17 Eli Lilly and Company Combination therapy with notch and pd-1 or pd-l1 inhibitors
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
EP3554502A4 (en) 2016-12-16 2021-01-06 Pipeline Therapeutics, Inc. METHOD FOR TREATMENT OF COCHLEA SYNAPTOPATHY
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
AU2018359907A1 (en) 2017-11-06 2020-05-07 Fred Hutchinson Cancer Center Combination of a cell therapy and a gamma secretase inhibitor
US11590152B2 (en) 2018-01-26 2023-02-28 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
AU2020307471A1 (en) 2019-06-24 2022-01-27 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting B-cell maturation antigen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9711537B (en) * 1996-12-23 1998-06-25 Athena Neurosciences Inc Eli L Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
UA74849C2 (en) 2000-11-17 2006-02-15 Lilly Co Eli Lactam
TW200502221A (en) * 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
JP2006520396A (ja) * 2003-03-14 2006-09-07 アストラゼネカ・アクチエボラーグ 新規なラクタム及びその使用

Also Published As

Publication number Publication date
JP5385904B2 (ja) 2014-01-08
AU2008287124A1 (en) 2009-02-19
CN101778826A (zh) 2010-07-14
EA201070278A1 (ru) 2010-06-30
JP2010536766A (ja) 2010-12-02
EA017286B1 (ru) 2012-11-30
CA2694209A1 (en) 2009-02-19
CA2694209C (en) 2013-09-17
BRPI0815135A2 (pt) 2015-02-03
US20100197660A1 (en) 2010-08-05
US8188069B2 (en) 2012-05-29
KR101136260B1 (ko) 2012-04-19
CN101778826B (zh) 2012-10-31
AU2008287124B2 (en) 2013-06-06
WO2009023453A1 (en) 2009-02-19
KR20100032924A (ko) 2010-03-26
EP2178844A1 (en) 2010-04-28

Similar Documents

Publication Publication Date Title
MX2009000884A (es) Derivados de piridizinona.
MY153915A (en) Organic compounds
MX2011005934A (es) Compuestos organicos.
AU2010246749A8 (en) Thiophene derivatives
GEP20156242B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
EA201070278A1 (ru) Ингибиторы гамма-секретазы
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
AU2009236256A8 (en) Small molecule inhibitors of the pleckstrin homology domain and methods for using same
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
MY151986A (en) Adamantyl diamide derivatives and uses of same
SI2134691T1 (sl) Derivati kvinolina kot PARP in TANK inhibitorji
MX2012004780A (es) Inhibidores de akt.
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
TW200745084A (en) Novel compounds
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
TW200738653A (en) Anthranilamide/2-amino-heteroarene carboxamide derivatives
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
UA99787C2 (en) Lactams as beta secretase inhibitors
MY153921A (en) Aminopyrazole derivatives
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
TW200738627A (en) Trialkylsilyl-indoles
MX2010004604A (es) Derivados de pirazol como inhibidores de 5-lo.
SG158091A1 (en) Imidazoazepinone compounds
PT1877367E (pt) Derivados do acetileno

Legal Events

Date Code Title Description
FG Grant or registration